CRISPR Therapeutics' (CRSP) "Neutral" Rating Reaffirmed at Cantor Fitzgerald

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report)'s stock had its "neutral" rating restated by investment analysts at Cantor Fitzgerald in a research note issued on Wednesday,Benzinga reports. Cantor Fitzgerald also issued estimates for CRISPR Therapeutics' FY2025 earnings at ($6.91) EPS.

Several other brokerages have also recently weighed in on CRSP. Royal Bank of Canada decreased their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a research report on Wednesday, February 12th. Evercore ISI upgraded shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and increased their target price for the stock from $60.00 to $99.00 in a research note on Friday, February 14th. HC Wainwright restated a "buy" rating and set a $65.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. StockNews.com raised CRISPR Therapeutics to a "sell" rating in a report on Thursday, February 13th. Finally, JMP Securities reissued a "market outperform" rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $74.40.

CRISPR Therapeutics Price Performance

Shares of CRSP traded down $2.52 during trading hours on Wednesday, hitting $47.91. The company's stock had a trading volume of 2,671,174 shares, compared to its average volume of 2,550,435. The business has a 50 day simple moving average of $42.25 and a two-hundred day simple moving average of $46.06. CRISPR Therapeutics has a 52-week low of $36.52 and a 52-week high of $91.10. The company has a market cap of $4.11 billion, a price-to-earnings ratio of -10.96 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Research analysts predict that CRISPR Therapeutics will post -5.16 earnings per share for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of the business's stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares of the company's stock, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Capital Market Strategies LLC purchased a new position in CRISPR Therapeutics during the 4th quarter valued at about $461,000. KBC Group NV grew its stake in shares of CRISPR Therapeutics by 2,047.4% in the 4th quarter. KBC Group NV now owns 60,514 shares of the company's stock worth $2,382,000 after buying an additional 57,696 shares during the last quarter. Capital Advisors Inc. OK increased its position in CRISPR Therapeutics by 8.1% during the 3rd quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company's stock valued at $14,122,000 after buying an additional 22,583 shares in the last quarter. Geode Capital Management LLC boosted its holdings in CRISPR Therapeutics by 3.6% in the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company's stock worth $47,383,000 after acquiring an additional 35,196 shares in the last quarter. Finally, State Street Corp grew its stake in shares of CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company's stock worth $140,611,000 after acquiring an additional 599,304 shares during the last quarter. Institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.